Results 81 to 90 of about 48,011 (239)

MicroRNAs as potential architects of immune dysregulation and megakaryocytic failure in immune thrombocytopenia

British Journal of Haematology, EarlyView.
Summary Immune thrombocytopenia (ITP) is a complex autoimmune disorder characterized by accelerated destruction of peripheral platelets and impaired megakaryopoiesis. While the cellular effectors, dysregulated T cells, hyperactive B cells and phagocytic macrophages are well characterized, the upstream epigenetic mechanisms orchestrating this ...
Zhenyu Liu, Johan Rebetz, Lamya Garabet, Waleed Ghanima, Peipei Xu, Hans Wadenvik, Drew Provan, Rick Kapur, John W. Semple   +8 more
wiley   +1 more source

Postoperative Care and Management in Pediatric Hematology‐Oncology Patients

European Journal of Haematology, EarlyView.
ABSTRACT Pediatric patients with hematologic and oncologic diseases often undergo surgical procedures as part of diagnosis and therapy. These include central venous catheter placements, tumor resections, lymph node and bone marrow biopsies, among others.
Shachi Srivatsa, Sara A. Mansfield
wiley   +1 more source

Application and analysis of compatible platelets matching via antigen avoidance

Zhongguo shuxue zazhi
[Objective] To investigate the application of antigen avoidance pattern for compatible platelets matching. [Methods] Samples from two patients with immune-mediated platelet transfusion refractoriness were screened for platelet antibodies using solid ...
WU Shaoyun, ZHENG Jianxun, JIANG Sujun, WU Shiquan   +3 more
doaj   +1 more source

Immune Mechanisms of Platelet Refractoriness

, 1998
Multiple platelet transfusions may prove ineffective in approximately 40% of patients treated for bone marrow aplasia. This condition is known as platelet refractoriness and is diagnosed by evaluating the corrected count increment following platelet ...
F. Fischetti, F. Tedesco
core   +1 more source

Post‐Transplant Bendamustine as a Platform for Immune Modulation After Allogeneic Hematopoietic Cell Transplantation

European Journal of Haematology, EarlyView.
ABSTRACT Post‐transplant cyclophosphamide (PT‐CY) remains the standard of care for graft‐versus‐host disease (GvHD) prophylaxis in haploidentical hematopoietic cell transplantation (HCT), yet relapse, delayed immune reconstitution, infections, and organ toxicity represent persistent and clinically meaningful limitations.
Megan J. Cracchiolo, Richard J. Simpson, Emmanuel Katsanis   +2 more
wiley   +1 more source

Platelet Transfusion: And Update on Challenges and Outcomes

Journal of Blood Medicine, 2020
Pilar Solves Alcaina Blood Bank, Hematology Service, Hospital Universitari I Politècnic La Fe, Valencia, CIBERONC, Instituto Carlos III, Madrid, SpainCorrespondence: Pilar Solves AlcainaBlood Bank, Hematology Service, Hospital Universitari I Polit&
Solves Alcaina P
doaj  

Longitudinal Changes in Transfusion Practice in Myelodysplastic Syndromes: A Population Data‐Linkage Study

European Journal of Haematology, EarlyView.
ABSTRACT Background Real‐world data on transfusion needs of patients with myelodysplastic syndromes (MDS), and the impacts of disease‐modifying therapies (DMTs) are sparse. In 2011, 5‐azacitidine became the first funded DMT for MDS and chronic myelomonocytic leukaemia (CMML) patients in Australia and national patient blood management (PBM) guidelines ...
Allison Mo, Le Thi Phuong Thao, Cameron Wellard, Erica M. Wood, Jake Shortt, Zoe K. McQuilten   +5 more
wiley   +1 more source

Rare Bleeding Disorders and Bleeding Disorder of Unknown Cause: Current Understanding and Recent Developments

Haemophilia, EarlyView.
ABSTRACT Rare bleeding disorders (RBDs) represent a diverse group of inherited conditions involving coagulation factors or platelets. These conditions, such as Glanzmann thrombasthenia (GT) or severe coagulation factor deficiencies, are uncommon. In contrast, bleeding disorder of unknown cause (BDUC) is a diagnosis of exclusion without an identifiable ...
Alessandro Casini, Robert Klamroth, Bauke Haisma, Dino Mehic, Saskia E. M. Schols   +4 more
wiley   +1 more source

Platelet Transfusion Refractoriness

, 2013
Platelet transfusion has been used for decades as a highly beneficial therapeutic measure to prevent or stop bleeding in patients with severe thrombocytopenia by increasing the circulatory platelet numbers.
Mortazavi, Reza; id_orcid
core  

Management of Breakthrough Bleeding During Emicizumab Prophylaxis in Acquired Haemophilia A: Data From the GTH‐AHA‐EMI Study

Haemophilia, EarlyView.
ABSTRACT Introduction The GTH‐AHA‐EMI study showed that emicizumab reduces bleeding in patients with acquired haemophilia A (AHA). However, 22 clinically relevant new bleeds (CRNB) occurred in 14 of the 47 study patients, most of which required haemostatic treatment.
Halet Türkantoz, Christiane Dobbelstein, Richard Greil, Christina Hart, Robert Klamroth, Paul Knöbl, Johannes Oldenburg, Christian Pfrepper, Ulrich Sachs, Inga M. Schimansky, Karolin Trautmann‐Grill, Andreas Tiede   +11 more
wiley   +1 more source